RET (Y791F)
Sign in to save this workspaceRET · Variant type: point · HGVS: p.Y791F
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Ponatinib | 99.9% | 0.1% | 78.23 |
| 2 | Pralsetinib | 99.8% | 0.2% | 93.43 |
| 3 | Lenvatinib | 99.2% | 0.8% | 97.74 |
| 4 | Selpercatinib | 99.2% | 0.8% | 96.72 |
| 5 | Regorafenib | 99.1% | 0.9% | 95.99 |
| 6 | Nintedanib | 99.0% | 1.0% | 90.23 |
| 7 | Fedratinib | 98.5% | 1.5% | 96.21 |
| 8 | Tivozanib | 98.3% | 1.7% | 92.42 |
| 9 | Alpelisib | 98.0% | 2.0% | 97.22 |
| 10 | Tenalisib | 97.6% | 2.4% | 97.98 |
| 11 | Entrectinib | 97.4% | 2.6% | 93.69 |
| 12 | Alectinib | 97.1% | 2.9% | 95.49 |
| 13 | Brigatinib | 96.0% | 4.0% | 82.96 |
| 14 | Cabozantinib | 95.4% | 4.6% | 92.73 |
| 15 | Sorafenib | 95.0% | 5.0% | 96.72 |
| 16 | Gilteritinib | 93.8% | 6.2% | 88.97 |
| 17 | Axitinib | 91.7% | 8.3% | 93.23 |
| 18 | Vandetanib | 91.0% | 9.0% | 95.74 |
| 19 | Futibatinib | 89.3% | 10.7% | 98.48 |
| 20 | Sunitinib | 87.7% | 12.3% | 91.73 |
| 21 | Fostamatinib | 84.5% | 15.5% | 96.74 |
| 22 | Ibrutinib | 84.5% | 15.5% | 94.74 |
| 23 | Erdafitinib | 84.5% | 15.5% | 95.71 |
| 24 | Pazopanib | 81.1% | 18.9% | 97.49 |
| 25 | Avapritinib | 77.2% | 22.8% | 97.73 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Ponatinib | 99.9% | 100.0% | -0.1% |
| Pralsetinib | 99.8% | 100.0% | -0.2% |
| Lenvatinib | 99.2% | 98.8% | +0.4% |
| Selpercatinib | 99.2% | 100.0% | -0.8% |
| Regorafenib | 99.1% | 98.7% | +0.4% |
| Nintedanib | 99.0% | 100.0% | -1.0% |
| Fedratinib | 98.5% | 99.9% | -1.3% |
| Tivozanib | 98.3% | 99.7% | -1.5% |
| Alpelisib | 98.0% | 99.6% | -1.7% |
| Tenalisib | 97.6% | 98.5% | -0.9% |
| Entrectinib | 97.4% | 99.6% | -2.2% |
| Alectinib | 97.1% | 97.8% | -0.7% |
| Brigatinib | 96.0% | 94.9% | +1.1% |
| Cabozantinib | 95.4% | 97.5% | -2.1% |
| Sorafenib | 95.0% | 94.0% | +1.0% |
| Gilteritinib | 93.8% | 100.0% | -6.2% |
| Axitinib | 91.7% | — | — |
| Vandetanib | 91.0% | 98.6% | -7.5% |
| Futibatinib | 89.3% | 97.7% | -8.4% |
| Sunitinib | 87.7% | 97.2% | -9.5% |
| Fostamatinib | 84.5% | — | — |
| Ibrutinib | 84.5% | — | — |
| Erdafitinib | 84.5% | 94.7% | -10.2% |
| Pazopanib | 81.1% | — | — |
| Avapritinib | 77.2% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| pheochromocytoma_adrenal_gland | Adrenal | ref |
| PRAD | Prostate | ref |
| SKCM | Skin | ref |
| DLBC | Blood/Lymphatic System | ref |
| ALL | Other | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.3ms